Physician profile
Amanda Hansen
NPI 1184713729
$3,437.49
in general payments reported to CMS, 2019-2025
26 companies · $1,215 in 2025
The $1,215 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.12 · 2022: $367 · 2023: $425 · 2024: $1,361 · 2025: $1,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,001.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $951.28 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $668.78 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $236.32 | 2022-2025 | Evenity, Otezla, Repatha |
| Glaxosmithkline, LLC. | $208.28 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Antares Pharma, INC. | $200.49 | 2024-2025 | Xyosted |
| Exact Sciences Corporation | $189.07 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $170.39 | 2022-2025 | Ozempic |
| Abbvie INC. | $128.88 | 2024-2025 | |
| Axsome Therapeutics, INC. | $96.73 | 2024-2025 | Auvelity |
| Pfizer INC. | $79.28 | 2023-2025 | |
| Insulet Corporation | $66.43 | 2025 | Omnipod |
| Phathom Pharmaceuticals, INC. | $58.79 | 2024 | Voquezna |
| Corcept Therapeutics | $42.84 | 2024 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.03 | 2024-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $38.04 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $37.22 | 2023-2024 | Eliquis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.83 | 2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $34.47 | 2022-2024 | |
| Dexcom, INC. | $27.27 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $23.34 | 2024 | Freestyle Libre |
| Amarin Pharma, INC. | $21.13 | 2022 | |
| Verity Pharmaceuticals INC. | $18.26 | 2025 | Tlando |
| Merck Sharp & Dohme LLC | $17.42 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Boston Scientific Corporation | $15.91 | 2023 | |
| Jazz Pharmaceuticals INC. | $14.65 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.36 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.